VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase - Here's Why

Key Points

• VYNE Therapeutics’ trading volume increased 55% to 15,572 shares, while the stock slipped 0.6% to $25.20. The company has an $844.15 million market capitalization.
• Analyst sentiment remains cautious: three analysts rate the stock “Hold,” one rates it “Sell,” and the consensus rating is “Reduce.”
• VYNE reported a quarterly loss of $4.00 per share, beating the expected $9.00 loss, but revenue of $0.09 million fell short of the $0.20 million estimate. The company also paid a $19.00 special dividend in July.

VYNE Therapeutics Inc. (NASDAQ:VYNE - Get Free Report) saw an uptick in trading volume on Monday . 15,572 shares changed hands during trading, an increase of 55% from the previous session's volume of 10,032 shares.The stock last traded at $25.20 and had previously closed at $25.45.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce".

VYNE Therapeutics Trading Down 0.6%

The company has a market capitalization of $844.15 million, a price-to-earnings ratio of -66.55 and a beta of 2.00. The stock's fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.63.

VYNE Therapeutics (NASDAQ:VYNE - Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($4.00) EPS for the quarter, topping analysts' consensus estimates of ($9.00) by $5.00. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million. On average, analysts anticipate that VYNE Therapeutics Inc. will post -1.1 EPS for the current fiscal year.

VYNE Therapeutics Dividend Announcement

The firm also recently declared a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in VYNE Therapeutics in the fourth quarter valued at approximately $46,000. Rangeley Capital LLC lifted its position in shares of VYNE Therapeutics by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company's stock worth $71,000 after buying an additional 18,064 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics in the 3rd quarter valued at $74,000. Geode Capital Management LLC boosted its holdings in shares of VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company's stock valued at $131,000 after buying an additional 88,030 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of VYNE Therapeutics in the 4th quarter valued at $147,000. Hedge funds and other institutional investors own 83.78% of the company's stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company's lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.